// App-Quantinova.ai

4549 : Safety and activity of the investigational agent orteronel (ortl) without prednisone in men with nonmetastatic castration-resistant prostate cancer (nmCRPC) and rising prostate-specific antigen (PSA): Updated results of a phase II study.

Researchers

Presenter

  • Daniel J. George

Principal Investigators

  • Paul G. Corn

  • M. Dror Michaelson

  • Hans J. Hammers

  • Joshi J. Alumkal

  • Charles J. Ryan

  • Justine Yang Bruce

  • Susan Moran

  • Shih-Yuan Lee

  • Peter Mortimer

  • Maha Hussain

Medical Centers

  • University of Michigan Comprehensive Cancer Center, Ann Arbor, MI

  • Duke University Medical Center, Durham, NC

  • Massachusetts General Hospital Cancer Center, Boston, MA

  • UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

  • University of Wisconsin Comprehensive Cancer Center, Madison, WI

  • Oregon Health and Science University, Portland, OR

  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Circulating tumor cells

  • Prostate specific antigen

Drug/Treatment

  • Ketoconazole

  • Prednisone

  • Orteronel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved